Teladoc Health’s CEO, Jason Gorevic, is moderating expectations about the potential growth impact of glucagon-like peptide 1 (GLP-1) agonists on the company’s digital health weight management program. Despite the increasing popularity of GLP-1s for weight management, Gorevic noted that the response from Teladoc’s employer and health plan customers has been mixed.
This cautious stance reflects the varying levels of insurance coverage and acceptance of GLP-1s in the broader healthcare market, impacting how significantly these drugs might contribute to the expansion of Teladoc’s weight management offerings. The company is assessing the evolving landscape of GLP-1 usage and its implications for their digital health services.